Thymectacin

Thymectacin
Skeletal formula of thymectacin
Space-filling model of the thymectacin molecule
Identifiers
CAS Number 232925-18-7 YesY
PubChem (CID) 6440764
ChemSpider 4945015 N
Chemical and physical data
Formula C21H25BrN3O9P
Molar mass 574.3185 g/mol
3D model (Jmol) Interactive image
 NYesY (what is this?)  (verify)

Thymectacin (NB-1011, NB-101, N-[[5-[(E)-2-Bromovinyl]-2'-deoxyuridin-5'-O-yl]](phenoxy)phosphoryl]-L-alanine methyl ester) is an anticancer prodrug of brivudine monophosphate. It developed by New Biotics and it has entered in phase I clinical trials for colon cancer.[1]

References


Description of Thymectacin: Thymectacin, also known as NB-1011, is a small molecule phosphoramidate derivative of (E)-5-(2-bromovinyl)-2'-deoxyuridine with potential antineoplastic activity. Selectively active against tumor cells expressing high levels of thymidylate synthase (TS), BVdU pronucleotide analogue NB1011 is converted intracellularly by TS to bromovinyldeoxyuridine monophosphate (BVdUMP) which competes with the natural substrate, deoxyuridine monophosphate, for binding to TS. Unlike TS inhibitors, this agent is a reversible substrate for TS catalysis. Thus, TS retains activity and converts BVdUMP into cytotoxic metabolites.

This article is issued from Wikipedia - version of the 4/2/2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.